{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:12:31Z","timestamp":1781241151861,"version":"3.54.1"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clgc.2020.10.001","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T13:50:42Z","timestamp":1602597042000},"page":"e135-e147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Neoadjuvant Versus Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Microsimulation Model"],"prefix":"10.1016","volume":"19","author":[{"given":"Amanda E.","family":"Hird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3948-2057","authenticated-orcid":false,"given":"Diana E.","family":"Magee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas C.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Sander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikala","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish S.","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2020.10.001_bib1","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","article-title":"European Association of Urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update","volume":"68","author":"Roupr\u00eat","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2014.03.003","article-title":"A\u00a0systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib3","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2020.10.001_bib4","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2020.10.001_bib5","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2012.05.048","article-title":"A\u00a0systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer","volume":"62","author":"Meeks","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000463389","article-title":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with locally advanced bladder cancer","volume":"93","author":"Nieders\u00fcss-Beke","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.clgc.2020.10.001_bib7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12894-017-0305-4","article-title":"Adjuvant chemotherapy improves survival of patients with high-risk upper urinary tract urothelial carcinoma: a propensity score-matched analysis","volume":"17","author":"Fujita","year":"2017","journal-title":"BMC Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib8","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1177\/0272989X08315241","article-title":"The half-cycle correction explained: two alternative pedagogical approaches","volume":"28","author":"Naimark","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clgc.2020.10.001_bib10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5489\/cuaj.5022","article-title":"Age-stratified perioperative mortality after urological surgeries","volume":"12","author":"Wallace","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2020.10.001_bib11","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1089\/end.2015.0137","article-title":"A\u00a0comparison of 30-day perioperative outcomes in open versus minimally invasive nephroureterectomy for upper tract urothelial carcinoma: analysis of 896 patients from the American College of Surgeons\u2013National Surgical Quality Improvement Program Database","volume":"29","author":"Hanske","year":"2015","journal-title":"J\u00a0Endourol"},{"key":"10.1016\/j.clgc.2020.10.001_bib12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.eururo.2012.01.021","article-title":"Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma","volume":"61","author":"Cha","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.urolonc.2014.04.006","article-title":"Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration","volume":"32","author":"Fradet","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2020.10.001_bib14","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/iju.12884","article-title":"Prognostic factors of recurrent disease in upper urinary tract urothelial cancer after radical nephroureterectomy: subanalysis of the multi-institutional national database of the Japanese Urological Association","volume":"22","author":"Hara","year":"2015","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib15","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.eururo.2014.11.035","article-title":"A\u00a0systematic review and meta-analysis of clinicopathologic factors linked to intravesical recurrence after radical nephroureterectomy to treat upper tract urothelial carcinoma","volume":"67","author":"Seisen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5152\/tud.2018.19677","article-title":"Muscle-invasive bladder and urethral cancer recurrence after surgical management of upper tract urothelial carcinoma: a review of 305 patients","volume":"44","author":"Elawdy","year":"2018","journal-title":"Turk J Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib17","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.urolonc.2012.04.014","article-title":"Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma","volume":"31","author":"Kim","year":"2013","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2020.10.001_bib18","first-page":"1124","article-title":"Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy","volume":"165","author":"Holm\u00e4ng","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0090-4295(02)01705-3","article-title":"Comparison of WHO\/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression","volume":"60","author":"Samaratunga","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2020.10.001_bib20","first-page":"2195","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00345-017-2115-4","article-title":"Patterns and predictors of recurrence after open radical cystectomy for bladder cancer: a comprehensive review of the literature","volume":"36","author":"Mari","year":"2018","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib23","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/j.clgc.2016.12.025","article-title":"Palliative chemotherapy for bladder cancer: treatment delivery and outcomes in the general population","volume":"15","author":"Robinson","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2020.10.001_bib24","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/bju.12601","article-title":"Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base","volume":"114","author":"Smith","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2020.10.001_bib25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(99)02292-8","article-title":"Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International Collaboration of Trialists","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2020.10.001_bib26","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.clgc.2014.04.002","article-title":"Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation","volume":"12","author":"Khaled","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2020.10.001_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00345-015-1636-y","article-title":"Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine\/cisplatin","volume":"34","author":"van de Putte","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib28","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"issue":"3 pt 2","key":"10.1016\/j.clgc.2020.10.001_bib29","first-page":"964","article-title":"Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study","volume":"153","author":"Martinez-Pi\u00f1eiro","year":"1995","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib30","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/cncr.25050","article-title":"Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma","volume":"116","author":"Matin","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2020.10.001_bib31","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.28655","article-title":"Neoadjuvant chemotherapy improves\u00a0survival of patients with upper tract urothelial carcinoma","volume":"120","author":"Porten","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2020.10.001_bib32","first-page":"863","article-title":"Clinical impact of chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system","volume":"21","author":"Rashid","year":"2015","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.clgc.2020.10.001_bib33","doi-asserted-by":"crossref","first-page":"18797","DOI":"10.18632\/oncotarget.24694","article-title":"Does perioperative chemotherapy improve survival in upper tract urothelial carcinoma? A population based analysis","volume":"9","author":"Goldberg","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.clgc.2020.10.001_bib34","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1002\/cncr.25043","article-title":"Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy","volume":"116","author":"Lane","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.clgc.2020.10.001_bib35","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2008.07.018","article-title":"Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience","volume":"55","author":"Donat","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","article-title":"Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer","volume":"260","author":"Merkow","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.clgc.2020.10.001_bib37","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"Griffiths","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2020.10.001_bib38","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","article-title":"Optimal management of high-risk T1G3 bladder cancer: a decision analysis","volume":"4","author":"Kulkarni","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.clgc.2020.10.001_bib39","article-title":"Management of reducible ventral hernias: clinical outcomes and cost-effectiveness of repair at diagnosis versus watchful waiting","author":"Wolf","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.clgc.2020.10.001_bib40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5489\/cuaj.502","article-title":"Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: adjusting for the burden of ensuing chronic kidney disease","volume":"7","author":"Klinghoffer","year":"2013","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2020.10.001_bib41","first-page":"47","article-title":"Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia","volume":"21","author":"Nam","year":"2018","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.clgc.2020.10.001_bib42","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/sj.bjc.6600203","article-title":"Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients\u2019 utilities and treatment preferences","volume":"86","author":"de Boer","year":"2002","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2020.10.001_bib44","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s00345-015-1484-9","article-title":"Prognostic value of systemic inflammatory responses in patients with upper urinary tract urothelial carcinoma","volume":"33","author":"Kim","year":"2015","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib45","first-page":"e1166","article-title":"Phase II trial of neoadjuvant chemotherapy followed by extirpative surgery for patients with high grade upper tract urothelial carcinoma (HG UTUC): results from ECOG-ACRIN 8141","volume":"199","author":"Hoffman-Censits","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2165\/11588250-000000000-00000","article-title":"Using QALYs in cancer: a review of the methodological limitations","volume":"29","author":"Garau","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clgc.2020.10.001_bib47","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1056\/NEJM199808063390606","article-title":"Gains in life expectancy from medical interventions\u2014standardizing data on outcomes","volume":"339","author":"Wright","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2020.10.001_bib48","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A\u00a0randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2020.10.001_bib49","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2020.10.001_bib50","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1056\/NEJM199101173240305","article-title":"Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model","volume":"324","author":"Hillner","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2020.10.001_bib51","article-title":"Adjuvant versus salvage radiotherapy for patients with adverse pathological findings following radical prostatectomy: a decision analysis","volume":"2","author":"Wallis","year":"2017","journal-title":"MDM Policy Pract"},{"key":"10.1016\/j.clgc.2020.10.001_bib52","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.tranon.2017.10.008","article-title":"Molecular characterization of urothelial carcinoma of the bladder and upper urinary tract","volume":"11","author":"Lee","year":"2018","journal-title":"Transl Oncol"},{"key":"10.1016\/j.clgc.2020.10.001_bib53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3389\/fonc.2018.00463","article-title":"Neoadjuvant vs. adjuvant chemotherapy in muscle invasive bladder cancer (MIBC): analysis from the RISC database","volume":"8","author":"Del Bene","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.clgc.2020.10.001_bib54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.5489\/cuaj.5022","article-title":"Age-stratified perioperative mortality after urological surgeries","volume":"12","author":"Wallace","year":"2018","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2020.10.001_bib55","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1089\/end.2015.0137","article-title":"A\u00a0comparison of 30-day perioperative outcomes in open versus minimally invasive nephroureterectomy for upper tract urothelial carcinoma: analysis of 896 patients from the American College of Surgeons\u2013National Surgical Quality Improvement Program Database","volume":"29","author":"Hanske","year":"2015","journal-title":"J\u00a0Endourol"},{"key":"10.1016\/j.clgc.2020.10.001_bib56","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","article-title":"Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial","volume":"395","author":"Birtle","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2020.10.001_bib57","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000463389","article-title":"Neoadjuvant chemotherapy with gemcitabine plus cisplatin in patients with locally advanced bladder cancer","volume":"93","author":"Nieders\u00fcss-Beke","year":"2017","journal-title":"Oncology"},{"key":"10.1016\/j.clgc.2020.10.001_bib58","first-page":"1124","article-title":"Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy","volume":"165","author":"Holm\u00e4ng","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib59","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0090-4295(02)01705-3","article-title":"Comparison of WHO\/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression","volume":"60","author":"Samaratunga","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2020.10.001_bib60","first-page":"69","article-title":"Bilateral metachronous ureteral and renal pelvic carcinomas: incidence, clinical presentation, histopathology, treatment and outcome","volume":"175","author":"Holm\u00e4ng","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib61","doi-asserted-by":"crossref","first-page":"e535","DOI":"10.1016\/j.clgc.2016.12.025","article-title":"Palliative chemotherapy for bladder cancer: treatment delivery and outcomes in the general population","volume":"15","author":"Robinson","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2020.10.001_bib62","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/bju.12601","article-title":"Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base","volume":"114","author":"Smith","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2020.10.001_bib63","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","article-title":"Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"67","author":"Zargar","year":"2015","journal-title":"Eur Urol"},{"issue":"3 pt 2","key":"10.1016\/j.clgc.2020.10.001_bib64","first-page":"964","article-title":"Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study","volume":"153","author":"Martinez-Pi\u00f1eiro","year":"1995","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib65","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.1016\/j.clgc.2014.04.002","article-title":"Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation","volume":"12","author":"Khaled","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2020.10.001_bib66","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2020.10.001_bib67","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eururo.2008.07.018","article-title":"Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience","volume":"55","author":"Donat","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib68","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/SLA.0000000000000378","article-title":"Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer","volume":"260","author":"Merkow","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.clgc.2020.10.001_bib69","article-title":"Management of reducible ventral hernias: clinical outcomes and cost-effectiveness of repair at diagnosis versus watchful waiting","author":"Wolf","year":"2017","journal-title":"Ann Surg"},{"key":"10.1016\/j.clgc.2020.10.001_bib70","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1371\/journal.pmed.0040284","article-title":"Optimal management of high-risk T1G3 bladder cancer: a decision analysis","volume":"4","author":"Kulkarni","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.clgc.2020.10.001_bib71","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.eururo.2012.01.021","article-title":"Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma","volume":"61","author":"Cha","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.10.001_bib72","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.urolonc.2014.04.006","article-title":"Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration","volume":"32","author":"Fradet","year":"2014","journal-title":"Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767320302287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767320302287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:32:55Z","timestamp":1761564775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767320302287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1558767320302287"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2020.10.001","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoadjuvant Versus Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Microsimulation Model","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2020.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}